In a groundbreaking development for the treatment of muscular dystrophies, IPS HEART received Orphan Drug Designation (ODD) from the U.S. FDA on January 13th, 2025, for its innovative stem cell therapy, GIVI-MPCs. GIVI-MPCs are mesenchymal progenitor cells derived from induced pluripotent stem cells (iPSCs) that have the potential to treat Becker Muscular Dystrophy (BMD). This milestone recognizes the therapy’s unprecedented ability to generate new skeletal muscle containing full-length dystrophin—a crucial protein missing or defective in individuals with BMD.
IPS Heart’s unique iPSC-derived mesenchymal progenitor cells (MPCs) appear to exert their therapeutic effects by forming new muscle tissue and restoring functional dystrophin, even in advanced disease states where muscle loss has occurred. Unlike existing treatments, which predominantly focus on delivering partial-length synthetic dystrophin via gene therapy, GIVI-MPCs offer a transformative approach to not only address the underlying cause of the disease but also to regenerate muscle tissue using multipotent progenitor cells.
A Pioneering Platform for Muscle Regeneration
Preclinical studies have demonstrated that GIVI-MPCs successfully generate human muscle with full-length dystrophin in multiple models of dystrophic and aging-related muscle degeneration. These include dystrophic pigs, young and aged Duchenne Muscular Dystrophy (DMD) mice, and a sarcopenia mouse model. This versatility highlights the platform’s potential to address not only Becker and Duchenne Muscular Dystrophies but also broader muscle-wasting conditions.
This latest ODD designation for BMD follows an earlier FDA recognition of GIVI-MPCs for Duchenne Muscular Dystrophy, further validating IPS HEART’s innovative platform. “While today the market is focused almost exclusively on gene therapies delivering partial-length synthetic dystrophin, our pluripotent stem cell therapy uniquely creates new muscle tissue while delivering full-length dystrophin,” said Rauf Ashraf, CEO of IPS HEART.
Expanding Therapeutic Potential
In addition to skeletal muscle regeneration, IPS HEART has developed ISX-9-CPCs, an iPSC-derived cardiac therapy designed to treat Duchenne cardiomyopathy and heart failure. ISX-9-CPCs create functional cardiac muscle, addressing the cardiac complications that frequently accompany muscular dystrophies. This dual focus on both skeletal and cardiac muscle regeneration underscores IPS HEART’s comprehensive strategy to combat the devastating effects of muscular dystrophy.
Following a successful second pre-Investigational New Drug (pre-IND) meeting with the FDA—attended by four FDA branch chiefs—IPS HEART has received approval for its proposed Phase I/II clinical trial design. This progress places the company on track to advance both GIVI-MPCs and ISX-9-CPCs into clinical trials, offering hope to patients with limited treatment options.
Collaborative Path to Clinical Trials
“With our successful FDA pre-IND meeting and ongoing developmental efforts, we believe we will be the first company to advance bona fide disease-modifying therapies into human clinical trials for these conditions,” said Ashraf. “Unlike existing drugs that provide primarily symptomatic relief, our therapies aim to address the root causes of muscle and cardiac degeneration.”
IPS HEART is actively seeking partnerships with pharmaceutical companies to expedite the clinical development of these therapies. The company’s presence at the J.P. Morgan Healthcare Conference underscores its commitment to forging collaborations that will bring these groundbreaking treatments to patients more quickly.
The potential of iPSC-derived therapies like GIVI-MPCs and ISX-9-CPCs represents a paradigm shift in the treatment of muscular dystrophies. By leveraging the regenerative capabilities of pluripotent stem cells, IPS HEART is pioneering a future where muscle and cardiac regeneration could transform outcomes for patients with BMD, DMD, and related conditions. As the company prepares for clinical trials, it stands at the forefront of a new era in regenerative medicine—one that prioritizes not just treatment but true healing and restoration.
You can view IPS Heart’s announcement of this news here.
The Future of iPSC-Derived MPC/MSC Therapeutics
While IPS Heart is using iPSCs to generate mesenchymal progenitor cells (MPCs), other companies are using iPSCs to generate mesenchymal stem cells (MSCs). Muscle progenitor cells (MPCs) are specialized for muscle repair and regeneration, derived from the myogenic lineage and committed to forming muscle tissue. In contrast, mesenchymal stem cells (MSCs) are multipotent, found in various tissues, and capable of broader differentiation, with strong immunomodulatory properties and applications across diverse tissue repair contexts.
Most notably, Cynata Therapeutics has been pioneering iPSC-derived MSC production technologies since 2011, supporting large-scale therapeutic development in collaboration with FUJIFILM CDI. Its first clinical trial with an iPSC-derived MSC therapeutic was initiated in 2017. There are also six other competitors who are developing iPSC-derived MSC therapeutics (iMSCs), including Bone Therapeutics, Brooklyn ImmunoTherapeutics, Citius Pharmaceuticals, Eterna Therapeutics, Implant Therapeutics, and Kiji Therapeutics.
